tbuckley/cabot-search huggingface dataset:
Facet‐Dependent Biodegradable Mn<sub>3</sub>O<sub>4</sub> Nanoparticles for Ameliorating Parkinson's Disease
Authors: Zhuojia Xu, Aihua Qu, Weiwei Wang, Meiru Lu, Baimei Shi, Chen Chen, Changlong Hao, Liguang Xu, Maozhong Sun, Chuanlai Xu, Hua Kuang
Journal: Advanced Healthcare Materials (2021)

Abstract Parkinson's disease (PD) is a common neurodegeneration disease. Unfortunately, there are no effective measures to prevent or inhibit this disease. In this study, biodegradable Mn 3 O 4 nanoparticles (NPs) in different shapes are prepared and enclosed them by {100}, {200} and {103} facets that exhibit facet‐dependent protection against neurotoxicity induced by oxidative damage in a cell model of PD. Notably, Mn 3 O 4 nanorods enclosed by {103} facets exhibit high levels of enzyme‐like activity to eliminate reactive oxygen specie in vitro. It is also determined that the uptake pathway of Mn 3 O 4 NPs into MN9D cells is mediated by caveolin. The data demonstrate that Mn 3 O 4 nanorods can be taken up by cells effectively and confer excellent levels of neuroprotection while the biodegradation of Mn 3 O 4 NPs in vivo is confirmed by photoacoustic image of Mn 3 O 4 NPs in brain at 60 d. Furthermore, the oxygen scavenging effect created by Mn 3 O 4 nanorods is successfully applied to a mouse model of PD; the amount of α ‐synuclein in the cerebrospinal fluid of PD mice is reduced by 61.2% in two weeks, thus demonstrating the potential application of facet‐directed Mn 3 O 4 NPs for the clinical therapy of neurodegenerative disease.
415P Comparison of cetuximab every 2 weeks versus standard once-weekly administration for the first-line treatment of RAS wild-type metastatic colorectal cancer among patients with left- and right-sided primary tumor location
Authors: S. Kasper, A-L. Cheng, M. Rouyer, C. Foch, F-X. Lamy, R. Esser, M. Batech, C.M.J. Wong, A. Zhang, T. Brodowicz, C. Zielinski
Journal: Annals of Oncology (2021)
Comprehensive Analysis of TP53 and KEAP1 Mutations and Their Impact on Survival in Localized- and Advanced-Stage NSCLC
Authors: Mohamed Mahde Saleh, Matthias Scheffler, Sabine Merkelbach-Bruse, Andreas Hans Scheel, Bastian Ulmer, Jürgen Wolf, Reinhard Buettner
Journal: Journal of Thoracic Oncology (2021)

IntroductionTP53 and KEAP1 are frequently mutated in NSCLC, but their prognostic value is ambiguous, particularly in localized stage tumors.MethodsThis retrospective cohort study included a total of 6297 patients with NSCLC who were diagnosed between November 1998 and February 2020. The primary end point was overall survival. Patients were diagnosed in a central pathology laboratory as part of the Network Genomic Medicine collaboration, encompassing more than 300 lung cancer-treating oncology centers in Germany. All patients underwent molecular testing, including targeted next-generation panel sequencing and in situ hybridization.ResultsA total of 6297 patients with NSCLC were analyzed. In 1518 surgically treated patients (Union for International Cancer Control [UICC] I–IIIA), truncating TP53 mutations and KEAP1 mutations were independent negative prognostic markers in multivariable analysis (hazard ratio [HR]TP53truncating = 1.43, 95% confidence interval [CI]: 1.07–1.91, p = 0.015; HRKEAP1mut = 1.68, 95% CI:1.24–2.26, p = 0.001). Consistently, these mutations were associated with shorter disease-free survival. In 4779 patients with advanced-stage (UICC IIIB–IV) tumors, TP53 mutations did not predict outcome in univariable analysis. In contrast, KEAP1 mutations remained a negative prognostic factor (HRKEAP1mut = 1.40, 95% CI: 1.23–1.61, p < 0.001) in patients with advanced-stage tumors. Furthermore, those with KEAP1-mutant tumors with co-occurring TP53 missense mutations had longer overall survival than those with KEAP1-mutant tumors with wild-type or truncating TP53 mutations.ConclusionsThis study found that TP53 and KEAP1 mutations were prognostic for localized and advanced-stage NSCLC. The increased relative hazard of harboring TP53 or KEAP1 mutations was comparable to an increase in one UICC stage. Our data suggest that molecular stratification on the basis of TP53 and KEAP1 mutation status should be implemented for localized and advanced-stage NSCLC to optimize and modify clinical decision-making.
335TiP Open-label, multinational, multicenter, phase IIIb/IV study of trastuzumab deruxtecan (T-DXd) in patients with or without baseline brain metastasis with previously treated advanced/metastatic human epidermal growth factor receptor 2–positive breast cancer (HER2+ BC): DESTINY-Breast12
Authors: N.U. Lin, E. Ciruelos, G. Jerusalem, V. Müller, N. Niikura, G. Viale, E. Oscroft, S. Anand, G. Walker, N. Harbeck
Journal: Annals of Oncology (2021)
698P Analysis of hard-to-treat subgroups from EV-301: A phase III trial of enfortumab vedotin (EV) vs chemotherapy for previously treated advanced urothelial carcinoma
Authors: J.E. Rosenberg, T. Powles, G.P. Sonpavde, Y. Loriot, I. Duran, J.L. Lee, N. Matsubara, C. Vulsteke, D. Castellano, R. Mamtani, S.S. Sridhar, H. Pappot, H.P. Gurney, J. Bedke, M.S. van der Heijden, M. Campbell, C. Wu, M. Matsangou, D.P. Petrylak
Journal: Annals of Oncology (2021)
1132P In vivo morphological segmentation of tumor by OCT-elastography
Authors: A.A. Plekhanov, M.A. Sirotkina, E.V. Gubarkova, A.A. Sovetsky, S.S. Kuznetsov, A.L. Matveyev, L.A. Matveev, E.V. Zagaynova, G.V. Gelikonov, V.Y. Zaitsev, N.D. Gladkova
Journal: Annals of Oncology (2021)
722O Randomised phase II trial of olaparib compared to weekly paclitaxel or olaparib plus cediranib in patients with platinum-resistant ovarian cancer (OCTOVA)
Authors: S. Nicum, J. Holmes, N. McGregor, R. Dunn, L. Collins, S. Kaye, I. McNeish, R.M. Glasspool, M. Hall, R. Roux, A. Michael, S. Banerjee, R. Kristeleit, G. Jayson, A. Clamp, A. Mansouri
Journal: Annals of Oncology (2021)
1613P What are the barriers to routine clinical use of teleconsultation in oncology? A retrospective study on patient’s and their physician’s satisfaction with 603 video teleconsultations
Authors: T. Mottet, P. Soubeyran, Y. Godbert, M. Cabart, G. Roubaud, C. Chakiba, K. Bourcier, L. Haik, C. Lebreton, A. Floquet, H. Charitansky, M. Fournier, M. Toulmonde, S. Pernot, M. Annonay, S. Enfedaque, S. Cassauba, A. Italiano, S. Mathoulin-Pelissier, N. Quenel Tueux
Journal: Annals of Oncology (2021)
Guide sheath <i>versus</i> non-guide sheath method for endobronchial ultrasound-guided biopsy of peripheral pulmonary lesions: a multicentre randomised trial
Authors: Masahide Oki, Hideo Saka, Tatsuya Imabayashi, Daisuke Himeji, Yoichi Nishii, Harunori Nakashima, Daisuke Minami, Shotaro Okachi, Yasuyuki Mizumori, Masahiko Ando
Journal: European Respiratory Journal (2021)

Guide sheaths (GSs) have been widely used during radial probe endobronchial ultrasound-guided transbronchial biopsy (rEBUS-TBB) of peripheral pulmonary lesions. However, it remains unknown whether a GS enhances the diagnostic yield. We compared the diagnostic yields of small peripheral pulmonary lesions between rEBUS-TBB with and without a GS.In eight institutions, patients with peripheral pulmonary lesions ≤30 mm in diameter were enrolled and randomised to undergo rEBUS-TBB with a GS (GS group) or without a GS (non-GS group) using a 4.0-mm thin bronchoscope, virtual bronchoscopic navigation and fluoroscopy. The primary end-point was the diagnostic yield of the histology specimens.A total of 605 patients were enrolled; ultimately, data on 596 (300 in the GS group and 296 in the non-GS group) with peripheral pulmonary lesions having a longest median diameter of 19.6 mm were analysed. The diagnostic yield of histological specimens from the GS group was significantly higher than that from the non-GS group (55.3% versus 46.6%; p=0.033). Interactions were evident between the diagnostic yields, procedures, lobar locations (upper lobe versus other regions; p=0.003) and lesion texture (solid versus part-solid nodules; p=0.072).The diagnostic yield for small peripheral pulmonary lesions afforded by rEBUS-TBB using a GS was higher than that without a GS.
In patients hospitalized with COVID-19, adding convalescent plasma to usual care did not reduce 28-d mortality
Authors: Joanna C. Dionne, Simon J.W. Oczkowski
Journal: Annals of Internal Medicine (2021)

Source CitationRECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet. 2021;397:2049-59. https://pubmed.ncbi.nlm.nih.gov/34000257/AbstractClinical Impact RatingsHospitalists: Infectious Disease: Critical Care: Pulmonology:
Mitochondrion‐Anchored Photosensitizer with Near Infrared‐I Aggregation‐Induced Emission for Near Infrared‐II Two‐Photon Photodynamic Therapy
Authors: Zhenyan He, Yuting Gao, Huimin Zhang, Ying Xue, Fanling Meng, Liang Luo
Journal: Advanced Healthcare Materials (2021)

Abstract Two‐photon photodynamic therapy (2P‐PDT) that employs photosensitizers (PSs) with 2P absorption is particularly intriguing in cancer treatment, in that 2P excitation enables precise spatial localization and deep tissue penetration. Here, a donor‐ π ‐acceptor PS (named TPBPy) with near infrared (NIR) aggregation‐induced emission (AIE) is designed and synthesized for imaging‐guided 2P‐PDT. The maximal photoluminescence (PL) peak of TPBPy is as high as 720 nm when it is encapsulated in liposomes. Upon 2P irradiation by a laser in NIR‐II window ( λ = 1000 nm), TPBPy exhibits strong NIR‐I PL in a multicellular tumor spheroids (MCTSs) model, showing an imaging depth of 210 µm that is significantly higher than upon one‐photon irradiation. Moreover, TPBPy localizes specifically on mitochondrion, an important organelle in cell oxidative metabolism and apoptosis. When exposed to the NIR‐II irradiation, TPBPy can efficiently generate singlet oxygen ( 1 O 2 ) and trigger cell death. The efficacy of TPBPy‐mediated 2P‐PDT has also been validated using 4T1 tumor mouse model, the growth of which is significantly suppressed upon NIR‐II laser irradiation. TPBPy herein serves as an excellent candidate to suppress deep tumor tissues through NIR‐II 2P‐PDT, and also renders a new paradigm to construct mitochondrion‐anchored AIE luminogens for future cancer theranostic applications.
Traumatic Brain Injury Recovery Trajectories in Patients With Disorders of Consciousness
Authors: Michael C. Smith, Mayur B. Patel, Oscar D. Guillamondegui
Journal: JAMA Neurology (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
922P Efficacy of immunotherapy (IO) and subsequent systemic treatment after failure of IO in patients with recurrent or metastatic head and neck cancer in a real-world setting
Authors: M. Pogorzelski, F. Lauri, T. Hilser, J. Hense, S. Ting, B. Kansy, T. Gauler, M. Stuschke, K.W. Schmid, S. Lang, G. Zaun, V. Grünwald, M. Schuler, S. Kasper
Journal: Annals of Oncology (2021)
Fludarabine/Melphalan 100 Conditioning Therapy Followed By Allogeneic Hematopoietic Cell Transplantation for Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis
Authors: Han-Seung Park, Jung-Hee Lee, Je-Hwan Lee, Eunji Choi, Sun-Hye Ko, Miee Seol, Young-Shin Lee, Young-Ah Kang, Mijin Jeon, Kyoo Hyung Lee
Journal: Blood (2017)
Improving sleep quality leads to better mental health: A meta-analysis of randomised controlled trials
Authors: Alexander J. Scott, Thomas L. Webb, Marrissa Martyn-St James, Georgina Rowse, Scott Weich
Journal: Sleep Medicine Reviews (2021)

The extent to which sleep is causally related to mental health is unclear.One way to test the causal link is to evaluate the extent to which interventions that improve sleep quality also improve mental health.We conducted a meta-analysis of randomised controlled trials that reported the effects of an intervention that improved sleep on composite mental health, as well as on seven specific mental health difficulties.65 trials comprising 72 interventions and N ¼ 8608 participants were included.Improving sleep led to a significant medium-sized effect on composite mental health (gþ¼À 0.53), depression (gþ¼À 0.63), anxiety (gþ¼À0.51),and rumination (gþ¼À0.49),as well as significant small-to-medium sized effects on stress (gþ¼À0.42),and finally small significant effects on positive psychosis symptoms (gþ¼À0.26).We also found a dose response relationship, in that greater improvements in sleep quality led to greater improvements in mental health.Our findings suggest that sleep is causally related to the experience of mental health difficulties.Future research might consider how interventions that improve sleep could be incorporated into mental health services, as well as the mechanisms of action that explain how sleep exerts an effect on mental health.
381TiP Vaccination with autologous dendritic cells loaded with autologous tumour homogenate in resected glioblastoma: A phase II study (CombiGVax)
Authors: L. Ridolfi, L. Gurrieri, N. Riva, V. Fausti, A. Bongiovanni, G. Di Menna, F. de Rosa, M. Guidoboni, L. Mercatali, J. Bulgarelli, F. Foca, M. Tazzari, S. Calpona, M. Petrini, A. Granato, E. Pancisi, M. Dall'Agata, L. Valmorri, L. Tosatto, T. Ibrahim
Journal: Annals of Oncology (2021)
Disruption of the endopeptidase ADAM10-Notch signaling axis leads to skin dysbiosis and innate lymphoid cell-mediated hair follicle destruction
Authors: Keiko Sakamoto, Seon-Pil Jin, Shubham Goel, Jay-Hyun Jo, Benjamin Voisin, Doyoung Kim, Vinod Nadella, Hai Liang, Tetsuro Kobayashi, Xin Huang, Clay Deming, Keisuke Horiuchi, Julia A. Segre, Heidi H. Kong, Keisuke Nagao
Journal: Immunity (2021)
Comprehensive Genomic Profiling Demonstrates Differences in Primary CNS Lymphoma and Systemic Diffuse Large B Cell Lymphoma and Reveals Biomarkers Indicating Potential Benefit from Immune Checkpoint Inhibitors
Authors: Eric A Severson, Jo-Anne Vergilio, Sugganth Daniel, Julia A Elvin, James Suh, Vincent A Miller, Philip J Stephens, Jeffrey S Ross, Shakti Ramkissoon
Journal: Blood (2017)
685P Genome-wide association meta-analysis identifies novel variants that correlate with efficacy outcomes in sunitinib-treated patients with metastatic renal cell carcinoma
Authors: M. Diekstra, J. Swen, L. van der Zanden, S. Vermeulen, E. Boven, R.H. Mathijssen, A. Oskarsdottir, E. Oosterwijk, A. Cambon-Thomsen, D. Castellano, A. Fritsch, J. Garcia-Donas, C. Rodriguez-Antona, U. Jaehde, T. Rafnar, K. Stefansson, S. Bohringer, M. Kubo, L. Kiemeney, H-J. Guchelaar
Journal: Annals of Oncology (2021)
1179P The effect of neoadjuvant chemotherapy / chemoradiotherapy on tumor tissue PD-L1 and VISTA expression levels in non-small cell lung cancers (NSCLC)
Authors: O. Akdogan, O. Sutcuoglu, B. Öğüt, N. Akyurek, N. Özdemir, A. Özet, O. Yazıcı
Journal: Annals of Oncology (2021)
LBA2 Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Randomized, double-blind, phase III KEYNOTE-826 study
Authors: N. Colombo, C. Dubot, D. Lorusso, V. Cáceres, K. Hasegawa, R. Shapira-Frommer, K.S. Tewari, P. Salman, E. Hoyos, E. Yañez, M. Gumus, M. Olivera Hurtado de Mendoza, V. Samouëlian, V. Castonguay, A. Arkhipov, S. Toker, K. Li, S.M. Keefe, B.J. Monk
Journal: Annals of Oncology (2021)
1621P Emotional distress in cancer patients during the first wave of the COVID-19 pandemic in Madrid
Authors: P. Toquero Diez, C. Blanco Fernández, B. Vera Cea, E. Méndez Carrascosa, A. Garrido García, O. Donnay Candil, A.I. Ballesteros García, J.M. Sánchez-Torres, P. Costas Rojo, R. Mondéjar Solís, B. Hernandez, M.D.P. López Martí, R. Colomer Bosch, N. Romero Laorden
Journal: Annals of Oncology (2021)
819TiP COLIBRI trial (GINECO-CE108b): A multicenter, window study evaluating immune impact and safety of nivolumab in combination with ipilimumab before initial radio-chemotherapy (RTCT) treatment for locally advanced cervix cancer
Authors: I.L. Ray-Coquard, M-C. Kaminsky-Forrett, F. Joly, L. Montané, D. Bello Roufai, A.M. Savoye, A. Angelergues, A-C. Hardy-Bessard, M.A. Mouret Reynier, E. Deluche, C. Caux, P. Saintigny, H. Péré, I. Treilleux, S. Betrian, F. Lecuru
Journal: Annals of Oncology (2021)
75P Tumor mutational burden in clinical routine practice: Identifying the right threshold?
Authors: C. Dupain, T. Gutman, E. Girard, P. du Rusquec, M-P. Sablin, P. Tresca, C. Neuzillet, A. Vincent-Salomon, S. Antonio, C. Franck, M. Galut, Y. Allory, J. Cyrta, I. Guillou, J. Wong, C. Le Tourneau, I. Bièche, N. Servant, M. Kamal, J. Masliah-Planchon
Journal: Annals of Oncology (2021)
Inhibition of the BTK-IDO-mTOR axis promotes differentiation of monocyte-lineage dendritic cells and enhances anti-tumor T cell immunity
Authors: Madhav D. Sharma, Rafal Pacholczyk, Huidong Shi, Zuzana J. Berrong, Yousef Zakharia, Austin Greco, Chang-Sheng S. Chang, Sudharshan Eathiraj, Eugene Kennedy, Thomas Cash, Roni J. Bollag, Ravindra Kolhe, Ramses Sadek, Tracy L. McGaha, Paulo Rodriguez, Jessica Mandula, Bruce R. Blazar, Theodore S. Johnson, David H. Munn
Journal: Immunity (2021)
Does prevention pay off? Economic aspects of sports injury prevention: a systematic review
Authors: Christoph Lutter, Christophe Jacquet, Evert Verhagen, Romain Seil, Thomas Tischer
Journal: British Journal of Sports Medicine (2021)

To identify, summarise and critically assess economic evaluation studies on sports injury prevention strategies.Systematic review.PubMed, SportDiscuss.The current literature was searched following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Economic analyses published since 2010 were checked for inclusion. The methodological quality of the studies was assessed using the Oxford Level of Evidence for economic and decision analysis; underlying randomised controlled trials (RCTs) were rated according to the Physiotherapy Evidence Database (PEDro) Scale, and risk of bias was assessed using the Revised Cochrane risk-of-bias tool.Ten studies fulfilled the inclusion criteria. The quality assessment revealed limited data quality. For trial-based analysis, underlying RCTs were of good quality and had a low risk of bias. Prevention concepts for general injury reduction showed effectiveness and cost savings. Regarding specific injury types, the analysis of the studies showed that the best data are available for ankle, hamstring and anterior cruciate ligament injuries. Measures using specific training interventions were the predominant form of prevention concepts; studies investigating these concepts showed cost-effectiveness with total cost savings between €24.82 and €462 per athlete.Injury prevention strategies that were studied are cost-effective. However, estimates and outcomes vary throughout the included studies, and precluded pooling of existing data. Knowledge about the cost-effectiveness of evaluated prevention measures will help improve the acceptance and application of prevention initiatives.
<i>R</i><i>othia mucilaginosa</i> is an anti-inflammatory bacterium in the respiratory tract of patients with chronic lung disease
Authors: Charlotte Rigauts, Juliana Aizawa, Steven L. Taylor, Geraint B. Rogers, Matthias Govaerts, Paul Cos, Lisa Ostyn, Sarah Sims, Eva Vandeplassche, Mozes Sze, Yves Dondelinger, Lars Vereecke, Heleen Van Acker, Jodie L. Simpson, Lucy Burr, Anne Willems, Michael M. Tunney, Cristina Cigana, Alessandra Bragonzi, Tom Coenye, Aurélie Crabbé
Journal: European Respiratory Journal (2021)

Background Chronic airway inflammation is the main driver of pathogenesis in respiratory diseases such as severe asthma, chronic obstructive pulmonary disease, cystic fibrosis (CF) and bronchiectasis. While the role of common pathogens in airway inflammation is widely recognised, the influence of other microbiota members is still poorly understood. Methods We hypothesised that the lung microbiota contains bacteria with immunomodulatory activity which modulate net levels of immune activation by key respiratory pathogens. Therefore, we assessed the immunomodulatory effect of several members of the lung microbiota frequently reported as present in CF lower respiratory tract samples. Results We show that Rothia mucilaginosa , a common resident of the oral cavity that is also often detectable in the lower airways in chronic disease, has an inhibitory effect on pathogen- or lipopolysaccharide-induced pro-inflammatory responses, in vitro (three-dimensional cell culture model) and in vivo (mouse model). Furthermore, in a cohort of adults with bronchiectasis, the abundance of Rothia species was negatively correlated with pro-inflammatory markers (interleukin (IL)-8 and IL-1β) and matrix metalloproteinase (MMP)-1, MMP-8 and MMP-9 in sputum. Mechanistic studies revealed that R. mucilaginosa inhibits NF-κB pathway activation by reducing the phosphorylation of IκBα and consequently the expression of NF-κB target genes. Conclusions These findings indicate that the presence of R. mucilaginosa in the lower airways potentially mitigates inflammation, which could in turn influence the severity and progression of chronic respiratory disorders.
695P Drug-drug interactions between pazopanib and proton pump inhibitors may significantly affect clinical outcome of patients affected by metastatic renal cell carcinoma
Authors: M. Del Re, N. Brighi, M. Rizzo, F. Paolieri, S.E. Rebuzzi, T. Beninato, S. Crucitta, C. Mercinelli, N. Gri, S. Puglisi, E. Verzoni, S. Bleve, F. Cucchiara, G. Procopio, G. Fornarini, L. Galli, C.G. Porta, U. De Giorgi, R. Danesi
Journal: Annals of Oncology (2021)
409P Real-world outcomes from cisplatin versus mitomycin plus fluoropyrimidine and radiation for localized squamous cell carcinoma of the anus (SCCA)
Authors: R.P. Riechelmann, A.K. Coutinho, G.S. Fernandes, R.F. Weschenfelder, D.R. Rocha Filho, L.A. Schlittler, J.F. Rego, R.G. de Jesus, G.C.D.L. Gossling, R.D. Peixoto
Journal: Annals of Oncology (2021)
1552P Magnitude of clinical benefit of cancer drugs used in advanced soft tissue sarcomas and GIST
Authors: R. Teres Lleida, P. Cerda Serda, B. Martin Cullell, M. Borrell Puy, A. Bujosa, P. Gallardo Melo, J. Gavira Diaz, J.C. Tapia, M. Aguado Sorolla, A. Piedra-Cascon, A. Tibau, A. Lopez Pousa, A. Sebio Garcia
Journal: Annals of Oncology (2021)
1676P Nutritional assessment in the era of targeted therapies in advanced non-small cell lung cancer (aNSCLC) oncogene-addicted patients
Authors: A.M. Morelli, I. Capizzi, C. Pisano, M. De Filippis, S. Carnio, A. Alemanni, M. Tinivella, P. Pedrazzoli, R. Caccialanza, V. Bertaglia, E. Capelletto, P. Bironzo, M.L. Reale, M. Tampellini, S. Novello
Journal: Annals of Oncology (2021)
741P Immune features of high-grade ovarian cancer associated with exceptional disease free survival (DFS): An analysis from VIVROVAIRE, a GINECO/GINEGEPS study
Authors: L. Mourani, E. Yaniz-Galende, C. Genestie, F. Gernier, H. De Saint Basile, P. Follana, A. Floquet, O. Tredan, E. Kalbacher, N. Dohollou, D. Berton, J. Alexandre, A. Zannetti, N. Raban, M-C. Kaminsky-Forrett, P. Pautier, G. Ferron, F. Joly, F. Blanc-Durand, A. Leary
Journal: Annals of Oncology (2021)